Basic information: Hepatocellular carcinoma intervention is a kind of regional local chemotherapy by injecting anti-cancer drugs or embolic agents into the hepatic artery through the femoral artery cannula. It is currently the preferred method of non-open surgery for hepatocellular carcinoma, and its efficacy has been confirmed. Treatment methods: Among hepatocellular carcinoma, vascular interventional therapy is the most clinically used. It is mainly selective hepatic artery perfusion therapy, selective hepatic artery embolization, and selective hepatic artery chemoembolization. The main physiological basis is that the blood supply of normal hepatocytes is 20%-25% from the hepatic artery and 75%-85% from the portal vein. In primary hepatocellular carcinoma, 90%-95% of the blood supply comes from the hepatic artery, which provides the anatomical basis for vascular intervention for hepatocellular carcinoma. The specific technical methods of all three are the same, which is to puncture a small opening of about 3-5mm on the skin, insert a tube from the artery to the blood supplying artery of hepatocellular carcinoma, and then administer the drug through the catheter. Selective hepatic arterial infusion (TAI) therapy involves intra-arterial infusion of the drug through a catheter at a dose equal to or less than that administered intravenously. This allows for higher local drug concentrations in the target cells and longer contact time with the lesion, and reduces the total systemic dose of drugs, resulting in improved efficacy and fewer side effects. The efficacy of chemotherapeutic drugs is positively correlated with the effective blood concentration of the drug at the tumor site and the contact time of the drug with the tumor. The efficacy of chemotherapeutic drugs is related to the effective blood concentration of the drug at the tumor site and the time of drug-tumor contact. Selective hepatic artery embolization (TAE) is to selectively inject embolic agents into tumor blood vessels and tumor blood supply arteries through catheters to block tumor blood supply and close tumor vascular beds, thus inhibiting tumor growth. This is equivalent to “starving” the tumor to death. Commonly used embolization agents include gelatin sponge, ultra-liquidated iodine oil, sodium alginate microspheres, etc. Selective hepatic artery chemoembolization (TACE) is the administration of both chemotherapeutic drugs and embolic agents via catheter. The tumor is destroyed by both routes. Indications: According to the NCCN American Cancer Treatment Guidelines, interventional therapy has been recognized as the treatment of choice for intermediate to advanced hepatocellular carcinoma. It adopts local targeted drug infusion, tumor vascular embolization and argon-helium cryoablation to focus on killing tumor cells, minimizing tumor load (reducing the number and volume of malignant tumors), and combining with CIK cell pervious immunotherapy and anti-tumor angiogenic drugs, which have achieved good therapeutic effects in clinical practice, effectively improving patients’ survival quality and prolonging survival time. It can also reverse the stage of liver cancer in some patients and transform unresectable liver cancer cases into resectable liver cancer cases. Treatment advantages: In recent years, liver cancer has become one of the major diseases that endanger the society and human health, and it has brought great pain and distress to human beings. In order to reduce the incidence of liver cancer, liver cancer interventional therapy is very necessary. The advantages of liver cancer interventional therapy are as follows: 1. Interventional treatment for hepatocellular carcinoma is simple and easy to operate, safe and reliable; 4. 7.It can be used as one of the important means of comprehensive treatment for advanced tumors. 8.The cost of hepatocellular carcinoma interventional therapy is relatively low.